Servier (Group)

https://www.servier.com

Servier is an independent international pharmaceutical company governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world. Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group’s development. As a world leader in hypertension and venous diseases and a major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurological diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient’s voice. Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion *

	Start	1954-01-01 established
	Industry	pharmaceutical
	Industry 2	cancer drug

	Street	50 rue Carnot
	City	92284 Suresnes Cedex
	Tel	+33-1-5572-6000
		Address record changed: 2024-01-05

Basic data	Employees	H: 10,001 to 50,00 (2024-12-31)
	Currency	EUR
	Annual sales	5,900,000,000 (revenues (2023/24) 2024-12-31)

		* Document for »About Section«: Servier. (9/8/25). "Press Release: Servier Acquires Potential Treatment for Fragile X Syndrome, the Most Common Genetic Cause of Autism Spectrum Disorder". Suresnes.

		Record changed: 2025-09-08